Mark brings 25 years of experience in life sciences to his role, including financial leadership of private and public, domestic and multinational companies. He most recently served as Co-founder and CFO of Secura Bio, a commercial-stage oncology therapeutics company. He previously held the role of CFO for Hyperion Therapeutics, Prometheus Laboratories, Veracyte, Sotera Wireless and Genoptix. Mark has extensive M&A experience with significant roles in transactions at Caremark, Dade Behring, Baxter, MedImmune, Prometheus and Genoptix. He additionally served in senior-level financial positions at Baxter Healthcare and Pricewaterhouse Coopers.
Mark holds a BA in Business Administration from Monmouth College. He also completed post-graduate studies at the University of Texas, Dallas and is a Certified Public Accountant.
Select Achievements
- Led finance, IT, human resources and facilities functions for newly formed pharma company that acquired two oncology products within 18 months and conducted commercial operations in 15+ countries
- Led finance, facilities and risk management for $100 million oncology diagnostic business acquired from Novartis, which was restructured to profitability and successfully divested within 20 months